SYK · News · 20261030N

Revenue Performance and Mix

STRYKER CORP · 2026-10-30 · Importance 36 · Surprise 14 · No source text

Stryker reported third-quarter 2026 revenue of $6.52 billion, up 7.7% year over year, but 0.9% below the Zacks consensus estimate of $6.57 billion. Organic sales increased 9.1% in MedSurg and Neurotechnology and 5.9% in Orthopaedics. Strong MedSurg demand and elevated capital equipment orders supported growth, while weaker hip and knee procedures, commercial execution challenges, and peripheral vascular supply constraints weighed on results.

Key facts

• Stryker's third-quarter revenues were $6.52 billion, up 7.7% both reportedly and organically, but missed the Zacks Consensus Estimate by 0.9%. source
• Stryker's third-quarter revenues were $6.52 billion, versus the Zacks Consensus Estimate of $6.57 billion, a 0.90% miss. source
• Stryker reported consolidated net sales of $6,520 million for the three months and $19,129 million for the nine months ended September 30, 2026. source
• Stryker's Q3 included one-time revenue from its Peripheral Vascular joint venture in China after a regulatory approval milestone was achieved in September. source
• Stryker's Q3 2026 organic sales growth was 7.7%, with 9.1% growth in MedSurg and Neurotechnology and 5.9% growth in Orthopaedics. source
• Stryker's net sales increased 7.7% year over year in the third quarter. source
• Stryker's hip sales decreased in the third quarter, while knee sales grew only slightly. source
• Stryker's stock declined 6.38% to $291.86 on Friday. source

Impact estimates